MedPlus Health Services Limited Initial Public Offer to open on December 13, 2021
· Price Band fixed at ₹780 to ₹796 per Equity Share of face value of ₹2 each of MedPlus Health Services Limited
· Offer to remain open from Monday, December 13, 2021 to Wednesday, December 15, 2021
· Bids can be made for a minimum of 18 Equity Shares and in multiples of 18 Equity Shares thereafter
Tuesday, December 07, 2021: MedPlus Health Services Limited (“MedPlus” or the “Company”), plans to open its Initial Public Offering (the “Offer”) on December 13, 2021.
The Price Band of the Offer has been fixed at ₹780 to ₹796 per Equity Share of face of ₹2 each. Bids can be made for a minimum of 18 Equity Shares and in multiples of 18 Equity Shares thereafter.
The Offer consists equity shares of face value of ₹2 each of MedPlus Health Services Limited comprising aggregating up to ₹13,982.95 million (the “Offer”), comprising of a fresh issue aggregating up to ₹6,000 million (the “Fresh Issue”) and an offer for sale of aggregating up to 7,982.95 million (the “Offer For Sale”). The Offer For Sale comprises of equity shares aggregating up to ₹6,230 million by PI Opportunities Fund – I (“Investor Selling Shareholder”), equity shares aggregating up to ₹1,070.00 million by S. S. Pharma LLC, equity shares aggregating up to ₹320.00 million by Shore Pharma LLC, equity shares aggregating up to ₹100.00 million by Natco Pharma Limited, equity shares aggregating up to ₹100.00 million by Time Cap Pharma Labs Private Limited, equity shares aggregating up to ₹71.28 million by A. Raghava Reddy, equity shares aggregating up to ₹42.28 million by K Prakurthi, equity shares aggregating up to ₹21.60 million by Navdeep Patyal, equity shares aggregating up to ₹14.70 million by Sangeeta Raju, equity shares aggregating up to ₹11.92 million by R. Venkat Reddy, equity shares aggregating up to ₹ 0.22 million by TK Kurien, equity shares aggregating up to ₹0.20 million by Nithya Venkataramani, equity shares aggregating up to ₹0.20 million by Atul Gupta, aggregating up to ₹0.20 million by Manoj Jaiswal, equity shares aggregating up to ₹0.20 million by Rahul Garg, equity shares aggregating up to ₹0.08 million by Kollengode Ramanathan Lakshminarayana and equity shares aggregating up to ₹0.08 million by Bijou Kurien (collectively, the “Other Selling Shareholders”).
The offer includes a reservation aggregating up to ₹50 million, for subscription by eligible employees (as defined hereinafter) (“Employee Reservation Portion”).
The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”). This Offer is in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs” and such portion the “QIB Portion”) provided that the Company and the Investor Selling Shareholder, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“Anchor Investor Portion”), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs.
Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders (“RIB”) in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA accounts and UPI ID (in case of RIBs using the UPI Mechanism), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see “Offer Procedure” on page 338.
The Net Proceeds from the Fresh Issue are proposed to be utilised for (i) Investment into Material Subsidiary, Optival for funding working capital requirements of Optival; and (ii) General corporate purposes.
The Equity Shares offered in this Offer are proposed to be listed at both BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”, together with BSE, the “Stock Exchanges”) post the listing.
MEDPLUS HEALTH SERVICES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with RoC. The RHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs, i.e. Axis Capital Limited, Credit Suisse Securities (India) Private Limited, Edelweiss Financial Services Limited and Nomura Financial Advisory and Securities (India) Private Limited at at www.axiscapital.co.in, www.credit-suisse.com, www.edelweissfin.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled “Risk Factors” on page 30 of the RHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision and such investment decision must be made solely on the basis of the Red Herring Prospectus once filed with the RoC.
The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“U.S. Securities Act”), or any state law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.